Placental mesenchymal stem cells: a unique source for cellular cardiomyoplasty.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23541427.
- Also identified by DOI 10.1016/j.athoracsur.2012.11.053.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In coronary heart disease, the use of stem cells for regeneration purposes has been broadly studied. Whereas bone marrow mesenchymal stem cells remain the most extensively investigated, other cell sources have been reported. Here we discuss and compare the characteristics of placenta-derived mesenchymal stem cells as a novel alternative cell source for cellular cardiomyoplasty. These cells are isolated from the human term placenta, which is normally discarded post partum. With their lack of ethical conflicts and young age, the readily available placenta-derived mesenchymal stem cells could be more suitable for myocardial regenerative therapy.
Medical subject headings
- Cardiomyoplasty
- Mesenchymal Stem Cell Transplantation